Transplantation And Cellular Therapy SCIE

國際簡稱：BIOL BLOOD MARROW TR 參考譯名：移植和細(xì)胞治療

主要研究方向：Medicine-Hematology 非預(yù)警期刊審稿周期：

《移植和細(xì)胞治療》(Transplantation And Cellular Therapy)是一本由Elsevier出版的以Medicine-Hematology為研究特色的國際期刊，發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評論文章和綜述文章，及時報道該領(lǐng)域相關(guān)理論、實踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn)，旨在促進(jìn)該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本開放期刊，近三年沒有被列入預(yù)警名單。

3區(qū) 中科院分區(qū)
Q1 JCR分區(qū)
295 年發(fā)文量
3.6 IF影響因子
開放是否OA
None 出版語言

Transplantation and Cellular Therapy, the official publication of the American Society for Transplantation and Cellular Therapy , focuses on current technology and knowledge in the interdisciplinary field of hematopoetic stem cell transplantation and the growing field of transplant and non-transplant cellular immunotherapies. The Journal publishes original research reports, practice guidelines, reviews, editorials, commentaries, and letters to the editor.This magazine is committed to promoting the development of scientific research and clinical applications in the fields of cell therapy and transplantation, providing a platform for scientists, doctors, and researchers engaged in related research worldwide to exchange and share the latest research results. As a professional journal focusing on the fields of cell therapy and transplantation, it provides a platform for researchers to showcase their research results and exchange academic views, which is of great significance for promoting the development of related fields.

[ 查看全部 ]

投稿咨詢加急咨詢

Transplantation And Cellular Therapy期刊信息

ISSN：2666-6375
出版語言：None
是否OA：開放
E-ISSN：2666-6367
出版地區(qū)：UNITED STATES
是否預(yù)警：否
出版商：Elsevier
開源占比：0.1987
Gold OA文章占比：76.35%
OA被引用占比：
出版國人文章占比：0
出版撤稿占比：
研究類文章占比：94.58%

Transplantation And Cellular Therapy CiteScore評價數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

1.602

1.113

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Transplantation	Q1	11 / 54	80%
大類：Medicine 小類：Hematology	Q1	30 / 137	78%
大類：Medicine 小類：Immunology and Allergy	Q2	82 / 233	65%
大類：Medicine 小類：Molecular Medicine	Q2	66 / 178	63%
大類：Medicine 小類：Cell Biology	Q2	128 / 285	55%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻(xiàn)的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個指標(biāo)。當(dāng)年CiteScore 的計算依據(jù)是期刊最近4年（含計算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。例如，2022年的 CiteScore 計算方法為：2022年的 CiteScore =2019-2022年收到的對2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻(xiàn)數(shù)量注：文獻(xiàn)類型包括：文章、評論、會議論文、書籍章節(jié)和數(shù)據(jù)論文。

Transplantation And Cellular Therapy中科院評價數(shù)據(jù)

中科院 2023年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	HEMATOLOGY 血液學(xué) IMMUNOLOGY 免疫學(xué) TRANSPLANTATION 移植	3區(qū) 3區(qū) 3區(qū)

中科院 2022年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
是	否	醫(yī)學(xué)	2區(qū)	HEMATOLOGY 血液學(xué) TRANSPLANTATION 移植 IMMUNOLOGY 免疫學(xué)	2區(qū) 2區(qū) 3區(qū)

Transplantation And Cellular Therapy JCR評價數(shù)據(jù)（2023-2024年最新版）

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：HEMATOLOGY	SCIE	Q2	25 / 97	74.7%
學(xué)科：IMMUNOLOGY	SCIE	Q2	86 / 181	52.8%
學(xué)科：TRANSPLANTATION	SCIE	Q1	7 / 31	79%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：HEMATOLOGY	SCIE	Q1	24 / 97	75.77%
學(xué)科：IMMUNOLOGY	SCIE	Q2	48 / 181	73.76%
學(xué)科：TRANSPLANTATION	SCIE	Q2	8 / 31	75.81%

Transplantation And Cellular Therapy歷年數(shù)據(jù)統(tǒng)計

影響因子

中科院分區(qū)

Transplantation And Cellular Therapy中國學(xué)者發(fā)文選摘

1、Alternative Transplantation With Post-Transplantation Cyclophosphamide in Aplastic Anemia: A Retrospective Report From the BMF-WG of Hunan Province, China
Author: Gong, Susu; Chen, Cong; Chen, Keke; Yang, Rui; Wang, Leyuan; Yang, Kaitai; Hu, Jian; Nie, Lin; Su, Tao; Xu, Yajing; He, Xianglin; Yang, Liangchun; Xiao, Hong; Fu, Bin

Journal: TRANSPLANTATION AND CELLULAR THERAPY. 2023; Vol. 29, Issue 1, pp. 480-480000000. DOI: 10.1016/j.jtct.2022.10.006
2、Machine learning algorithm as a prognostic tool for venous thromboembolism in allogeneic transplant patients
Author: Deng, Rui-Xin; Zhu, Xiao-Lu; Zhang, Ao-Bei; He, Yun; Fu, Hai-Xia; Wang, Feng-Rong; Mo, Xiao-Dong; Wang, Yu; Han, Wei; Chen, Huan; Chen, Yao; Yan, Chen-Hua; Wang, Jing-Zhi; Han, Ting -Ting; Chen, Yu -Hong; Chang, Ying-Jun; Xu, Lan -Ping; Huang, Xiao-Jun; Zhang, Xiao-Hui

Journal: TRANSPLANTATION AND CELLULAR THERAPY. 2023; Vol. 29, Issue 1, pp. 570-570000000000. DOI: 10.1016/j.jtct.2022.10.007
3、Characteristics of Engraftment Syndrome following Autologous Stem Cell Transplantation in Light Chain Amyloidosis with Renal Involvement
Author: Miao, Fujia; Ren, Guisheng; Guo, Jinzhou; Zhao, Liang; Xu, Weiwei; Huang, Xianghua

Journal: TRANSPLANTATION AND CELLULAR THERAPY. 2023; Vol. 29, Issue 2, pp. 1100-11000000000. DOI: 10.1016/j.jtct.2022.10.021
4、Donor CD7 Chimeric Antigen Receptor T Cell Bridging to Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Hematologic Malignancy
Author: Li, Zhihui; An, Na; Yang, Keyan; Meng, Fanqiao; Xu, Teng; Peng, Xiaojuan; Wen, Xiaopei; Li, Jing; Song, Yanzhi; Yang, Rui; Wu, Tong

Journal: TRANSPLANTATION AND CELLULAR THERAPY. 2023; Vol. 29, Issue 3, pp. 167-173. DOI: 10.1016/j.jtct.2022.11.013
5、A Prognostic Model Based on Clinical Biomarkers for Heart Failure in Adult Patients Following Allogeneic Hematopoietic Stem Cell Transplantation
Author: Zhang, Ao-Bei; Wang, Chen-Cong; Zhao, Peng; Tong, Ke-Ting; He, Yun; Zhu, Xiao-Lu; Fu, Hai-Xia; Wang, Feng-Rong; Mo, Xiao-Dong; Wang, Yu; Zhao, Xiang-Yu; Zhang, Yuan-Yuan; Han, Wei; Chen, Huan; Chen, Yao; Yan, Chen-Hua; Wang, Jing-Zhi; Han, Ting-Ting; Sun, Yu-Qian; Chen, Yu-Hong; Chang, Ying-Jun; Xu, Lan-Ping; Liu, Kai-Yan; Huang, Xiao-Jun; Zhang, Xiao-Hui

Journal: TRANSPLANTATION AND CELLULAR THERAPY. 2023; Vol. 29, Issue 4, pp. -. DOI: 10.1016/j.jtct.2022.12.008